Dolutegravir + Abacavir + Lamivudine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 50 mg / 600 mg / 300 mg
Reference Brands: Triumeq(US & EU)
Category:
Anti Viral
Dolutegravir + Abacavir + Lamivudine, sold as Triumeq, is a once-daily HIV-1 treatment combining three antiretrovirals in one pill. It offers strong viral suppression, is FDA and EMA approved, and is recommended for patients who are HLA-B*5701 negative.
Dolutegravir + Abacavir + Lamivudine is available in Tablet
and strengths such as 50 mg / 600 mg / 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dolutegravir + Abacavir + Lamivudine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dolutegravir + Abacavir + Lamivudine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dolutegravir + Abacavir + Lamivudine is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. Marketed under the brand name Triumeq, this once-daily oral tablet combines Dolutegravir (an integrase inhibitor), Abacavir, and Lamivudine (both NRTIs) to block HIV replication and reduce viral load. Approved by the US FDA and EMA, it is recommended for adults and adolescents who are HLA-B*5701 negative, with no resistance to any of the components. Triumeq simplifies HIV treatment by combining three powerful agents in one pill, offering high efficacy, strong viral suppression, and improved adherence for long-term HIV management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing